Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 365

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 365
---
 of the years indicated is presented below.
Year ended December 31,
Year ended December 31,
2022
2022
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────
in USD thousands
Salaries and other short-term employee benefits 2,298 2,425 2,018
Post-employment benefits 131 256 394
Other long-term benefits 35 31 29
Share-based compensation 1,011 1,030 370
3,475 3,742 2,811

NOTE 19 - SEGMENT REPORTING

The Company operates in asinglereportable operating segment - the development and commercialization of therapeutics. Its corporate headquarters and development activities are in Israel, while its revenues stem from activities carried out in the U. S. and Asia (primarily Greater China). In this regard, product sales relate to the Company’s direct commercialization activities in the U. S. from October 2023 through November 2024, while license revenues relate to outlicensing agreements entered into in Asia and in the U. S. in October 2023 and November 2024, respectively. Set forth below is a breakdown of revenues from external parties by geographic region.

             Year ended December 31,                                                     
             Year ended December 31,                                                     
             2022                                 2023                 2024              
             2022                                 2023                 2024              
 ─────────────────────────────────────────────────────────────────────────────────────────
             in USD thousands                                                            
  China                                   -                 4,610                14,957  
  U. S.                                   -                 190                  13,983  
                                          -                 4,800                28,940  

Substantially all of the Company’s non-current assets are located in Israel. See Notes 16 and 17 for information on customers representing 10% or more of total revenues.

F - 49

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 20 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

  Other receivables  

December 31,
2023
2023
─────────────────────────────────────────────────────────────────────
in USD thousands
Government institutions 245 455
Advance payments 480 91
Other 105 932
830 1,478

  Accounts payable and accruals  

December 31,
December 31